Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment
Status:
Not yet recruiting
Trial end date:
2026-12-30
Target enrollment:
Participant gender:
Summary
This study is a Phase II single-arm, open label, multicenter study to access the effects and
tolerability of fluzoparib combined with apatinib for maintenance treatment in
platinum-sensitive relapsed ovarian carcinoma .